JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors.

Innate immunity receptors are germline-encoded receptors that can sense molecular signatures of pathogens and cancer cells. Recent advances in immunology demonstrate the key role of these receptors in inflammation and initiation of subsequent immune responses, including adaptive immunity. Pharmaceutical interest in this field has grown with the retrospective demonstration that some marketed drugs targeting cancer or infectious diseases act via those receptors. In this review, I present an update on the scientific rationale for targeting one class of innate immunity receptor, the Toll-like receptors, and an update on the development status of corresponding drug candidates in infectious diseases, cancer, allergy and vaccines.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app